No-Reflow Prediction in Acute Coronary Syndrome During Percutaneous Coronary Intervention: The NORPACS Risk Score
- 1 April 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 17 (4) , e013738
Abstract
BACKGROUND: Suboptimal coronary reperfusion (no reflow) is common in acute coronary syndrome percutaneous coronary intervention (PCI) and is associated with poor outcomes. We aimed to develop and externally validate a clinical risk score for angiographic no reflow for use following angiography and before PCI. METHODS: We developed and externally validated a logistic regression model for prediction of no reflow among adult patients undergoing PCI for acute coronary syndrome using data from the Melbourne Interventional Group PCI registry (2005–2020; development cohort) and the British Cardiovascular Interventional Society PCI registry (2006–2020; external validation cohort). RESULTS: A total of 30 561 patients (mean age, 64.1 years; 24% women) were included in the Melbourne Interventional Group development cohort and 440 256 patients (mean age, 64.9 years; 27% women) in the British Cardiovascular Interventional Society external validation cohort. The primary outcome (no reflow) occurred in 4.1% (1249 patients) and 9.4% (41 222 patients) of the development and validation cohorts, respectively. From 33 candidate predictor variables, 6 final variables were selected by an adaptive least absolute shrinkage and selection operator regression model for inclusion (cardiogenic shock, ST-segment–elevation myocardial infarction with symptom onset >195 minutes pre-PCI, estimated stent length ≥20 mm, vessel diameter <2.5 mm, pre-PCI Thrombolysis in Myocardial Infarction flow <3, and lesion location). Model discrimination was very good (development C statistic, 0.808; validation C statistic, 0.741) with excellent calibration. Patients with a score of ≥8 points had a 22% and 27% risk of no reflow in the development and validation cohorts, respectively. CONCLUSIONS: The no-reflow prediction in acute coronary syndrome risk score is a simple count-based scoring system based on 6 parameters available before PCI to predict the risk of no reflow. This score could be useful in guiding preventative treatment and future trials.Keywords
This publication has 98 references indexed in Scilit:
- A note on estimating the Cox‐Snell R2 from a reported C statistic (AUROC) to inform sample size calculations for developing a prediction model with a binary outcomeStatistics in Medicine, 2020
- Effect of Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention on Microvascular Obstruction in Patients With Acute Myocardial InfarctionJAMA, 2019
- The relationship between serum rheumatoid factor level and no‐reflow phenomenon in patients with acute ST‐segment elevation myocardial infarction undergoing primary percutaneous coronary interventionJournal of Clinical Laboratory Analysis, 2018
- Mortality after percutaneous coronary revascularization: Prior cardiovascular risk factor control and improved outcomes in patients with diabetes mellitusCatheterization and Cardiovascular Interventions, 2016
- Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarctionCochrane Database of Systematic Reviews, 2015
- A Risk Score for No Reflow in Patients With ST‐Segment Elevation Myocardial Infarction After Primary Percutaneous Coronary InterventionClinical Cardiology, 2015
- Independent no-reflow predictors in female patients with ST-elevation acute myocardial infarction treated with primary percutaneous coronary interventionHeart and Vessels, 2011
- Predictors and Long‐term Prognosis of Angiographic Slow/No‐Reflow Phenomenon During Emergency Percutaneous Coronary Intervention for ST‐Elevated Acute Myocardial InfarctionClinical Cardiology, 2010
- Prediction of the no-reflow phenomenon during percutaneous coronary intervention using coronary computed tomography angiographyHeart and Vessels, 2010
- Comparison of combination therapy of adenosine and nitroprusside with adenosine alone in the treatment of angiographic no‐reflow phenomenonCatheterization and Cardiovascular Interventions, 2004